- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.06. | Mobia Medical, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 02.06. | BTIG initiates Mobia Medical stock coverage with buy rating | 1 | Investing.com | ||
| 02.06. | Wolfe Research initiates Mobia Medical stock with outperform rating | 1 | Investing.com | ||
| 02.06. | Goldman Sachs initiates Mobia Medical stock with buy rating on neuro tech | 2 | Investing.com | ||
| 02.06. | JPMorgan initiates Mobia Medical stock with Overweight rating | 1 | Investing.com | ||
| 02.06. | Mobia Medical: Goldman Sachs startet Coverage mit Kaufempfehlung dank Neurotechnologie | 5 | Investing.com Deutsch | ||
| MOBIA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 11.05. | Mobia Medical, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Mobia Medical, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 08.05. | Health stocks Odyssey, Mobia Medical disappoint on first day of trading | 1 | Seeking Alpha | ||
| 08.05. | MedTech firm Mobia Medical prices $150M IPO | 2 | Seeking Alpha | ||
| 08.05. | Nerve stimulation device maker Mobia Medical prices IPO at $15, the midpoint of the range | 2 | Renaissance Capital | ||
| 08.05. | Mobia Medical Prices $150 Mln Share IPO | 521 | AFX News | WASHINGTON (dpa-AFX) - Mobia Medical, Inc. (MOBI), on Friday announced that it has priced its initial public offering of 10 million common shares at $15.00 each.The medical device company expects... ► Artikel lesen | |
| 08.05. | Mobia Medical prices IPO at $15 per share, targets $150m | 1 | Investing.com | ||
| 08.05. | Mobia Medical, Inc.: Mobia Medical Announces Pricing of Initial Public Offering | 177 | GlobeNewswire (Europe) | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI) ("Mobia Medical"), a commercial-stage medical device company redefining stroke recovery for survivors living with... ► Artikel lesen | |
| 04.05. | Nerve stimulation device maker Mobia Medical sets terms for $150 million IPO, pricing this week | 1 | Renaissance Capital | ||
| 04.05. | Mobia Medical legt Preisspanne für Börsengang fest und strebt bis zu 160 Mio. US-Dollar an | 1 | Investing.com Deutsch | ||
| 04.05. | Mobia Medical prices IPO at up to $16 per share, targets $160m | 1 | Investing.com | ||
| 27.04. | Mobia Medical, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 18.04. | Nerve stimulation device maker Mobia Medical files for a $100 million IPO | 1 | Renaissance Capital | ||
| 17.04. | Mobia Medical, Inc. - S-1, General form for registration of securities | - | SEC Filings |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,500 | +2,25 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| INSULET | 137,95 | -0,65 % | Insulet beruft Jonathan Mazelsky in den Verwaltungsrat | ||
| LIFEWARD | 7,200 | 0,00 % | Lifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform | Veteran physician- medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience- mobility technologies, and metabolic disease... ► Artikel lesen | |
| IMUNON | 1,560 | -0,64 % | Imunon, Inc.: IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification | On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer... ► Artikel lesen | |
| LANTHEUS | 97,10 | +0,73 % | Lantheus receives Complete Response Letter for LNTH-2501 | ||
| INSPIRE MEDICAL SYSTEMS | 40,000 | -0,50 % | Inspire Medical Systems, Inc. - 8-K, Current Report | ||
| INSPIREMD | 0,600 | 0,00 % | InspireMD Inc.: InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures | MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced... ► Artikel lesen | |
| GT BIOPHARMA | 0,423 | -1,72 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| INOGEN | 5,950 | -2,46 % | Inogen Inc - S-8, Securities to be offered to employees in employee benefit plans | ||
| MYOMO | 0,912 | -3,39 % | MYOMO, INC. - 8-K, Current Report | ||
| INTELLIGENT BIO SOLUTIONS | 2,230 | +0,90 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,455 | +1,02 % | Incannex Healthcare: Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea | MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative... ► Artikel lesen | |
| LEXARIA BIOSCIENCE | 0,530 | 0,00 % | Lexaria Bioscience Corp.: Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule | KELOWNA, BC / ACCESS Newswire / June 25, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule... ► Artikel lesen | |
| GLUCOTRACK | 0,338 | +2,33 % | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| LENSAR | 5,690 | +1,07 % | LENSAR, Inc.: LENSAR Reports First Quarter 2026 Results and Provides Business Update | 7 ALLY Robotic Cataract Laser Systems® ("ALLY System") Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser... ► Artikel lesen |
Das Unternehmen MOBIA MEDICAL INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,75 % bei einem Aktienkurs von 14,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOBIA MEDICAL INC finden Sie auf Wallstreet Online.